Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21058249 | 0.75 | ALDH1A1 (0.40) | ALDH1A1TDP1CYP1A2CYP2D6ALOX15 | |
| SCHEMBL3210869 | 0.74 | ESR1 (0.30) | — | |
| SCHEMBL8926772 | 0.73 | — | — | |
| SCHEMBL830922 | 0.72 | ALOX15 (0.31) | ALOX15 | |
| SCHEMBL2656500 | 0.71 | ALDH1A1 (0.36) | ALDH1A1TDP1CYP1A2CYP2D6ALOX15 | |
| SCHEMBL2656497 | 0.71 | ALDH1A1 (0.36) | ALDH1A1TDP1CYP1A2CYP2D6ALOX15 | |
| SCHEMBL2656499 | 0.71 | ALDH1A1 (0.36) | ALDH1A1TDP1CYP1A2CYP2D6ALOX15 | |
| SCHEMBL975449 | 0.69 | — | — | |
| SCHEMBL25747479 | 0.69 | — | — | |
| SCHEMBL7561906 | 0.68 | MEN1 (0.31) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143451-B2 | Reacting a ketone with an allyl boron compound anc ammonia or ammonium salt; synthons | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2012-03-27 | — | — | US | disclosed |
| US-8143451-B2 | Reacting a ketone with an allyl boron compound anc ammonia or ammonium salt; synthons | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2012-03-27 | — | — | US | disclosed |
| US-20080139847-A1 | METHODS OF PREPARING TERTIARY CARBINAMINE COMPOUNDS | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2008-06-12 | — | — | US | disclosed |
| US-20080139847-A1 | METHODS OF PREPARING TERTIARY CARBINAMINE COMPOUNDS | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139847-A1 | METHODS OF PREPARING TERTIARY CARBINAMINE COMPOUNDS | INMT, CROCC, GNMT | ALDH1A1 1599/4885TDP1 3070/4885CYP1A2 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.